Table 5.
Results of Univariate and Multivariate Cox Regression for Overall Survival in SEER-Medicare Cohort of 63 Patients With Micropapillary Urothelial Carcinoma Treated With Radical Cystectomy
| Univariate Cox | Multivariate Cox | ||||
|---|---|---|---|---|---|
| Characteristic | Value | HR (95% CI) | P | HR (95% CI) | P |
| Age category | |||||
| 66-70 y | 17 (27) | Ref | Ref | ||
| 71-75 y | 22 (35) | 1.73 (0.76-3.96) | .196 | 1.56 (0.60-4.02) | .362 |
| 76-80 y | 13 (21) | 1.82 (0.67-4.92) | .238 | 1.43 (0.46-4.45) | .542 |
| 81+ y | 11 (17) | 1.96 (0.68-5.61) | .213 | 1.31 (0.36-4.72) | .683 |
| Sex assigned at birth | |||||
| Male | 52 (83) | Ref | Ref | ||
| Female | 11 (17) | 2.12 (0.89-5.04) | .091 | 1.58 (0.62-4.02) | .337 |
| T stage | |||||
| <T2 | <20%a | Ref | Ref | ||
| T2 | >30%a | 2.29 (0.62-8.44) | .214 | 2.76 (0.71-10.76) | .145 |
| T3/4 | 34 (54) | 7.10 (1.87-27.02) | .004 | 7.12 (1.71-29.72) | .007 |
| N stage | |||||
| N0 | 38 (60) | Ref | Ref | ||
| N+ | 25 (40) | 2.58 (1.31-5.06) | .006 | 3.02 (1.36-6.68) | .006 |
| NAC | |||||
| No NAC | 36 (57) | Ref | Ref | ||
| Non—cisplatin-based NAC | <20%a | 1.16 (0.49-2.71) | .738 | 0.98 (0.39-2.46) | .961 |
| Cisplatin-based NAC | >25%a | 0.60 (0.26-1.41) | .259 | 0.45 (0.15-1.30) | .140 |
Data are presented as n (%) unless otherwise indicated.
Abbreviations: CI = confidence interval; HR = hazard ratio; NAC = neoadjuvant chemotherapy; N = composite nodal stage; T = composite tumor stage.
a
Exact counts masked in compliance with Centers for Medicare and Medicaid Services/Surveillance, Epidemiology, and End Results (CMS/SEER) publication policy of no counts with fewer than 11 cases.